Protalix BioTherapeutics, Inc.

NYSE American:PLX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🥛 Dairy & Milk

💊 Pharmaceuticals

⚗️ Plastics

💉 Vaccines

Location

United States

Market Cap

USD 111.45 M

Share Price

USD 1.40

Avg Daily Volume

963,674

Change (1 day)

0.00%

Change (1 year)

19.66%

Change (YTD)

-25.53%

Protalix BioTherapeutics, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -25.53%

Protalix BioTherapeutics, Inc. Share Price Year-To-Date (YTD) return is -25.53% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Protalix BioTherapeutics, Inc. 52-week low Share Price is USD 3.07 on June 20, 2025, which is 119.29% above the current Share Price.
Protalix BioTherapeutics, Inc. 52-week low Share Price is USD 0.90 on June 20, 2025, which is -35.71% below the current Share Price.
Protalix BioTherapeutics, Inc. average Share Price for the last 52 weeks is USD 1.71.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NYSE American: PLX

Protalix BioTherapeutics, Inc.

CEO	Mr. Dror Bashan
IPO Date	May 15, 1998
Location	United States
Headquarters	2 University Plaza
Employees	213
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🥛 Dairy & Milk 💊 Pharmaceuticals ⚗️ Plastics 💉 Vaccines

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.